Market Intelligence, Clinical Progress, and High-Purity Reagents for Coagulation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for F7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | F7 Recombinant Protein (Zymogen/Activated) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native gamma-carboxylation. |
View F7 Products |
| Gene Delivery | F7 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View F7 Products |
| Benchmark Ab | Anti-F7 Recombinant Antibody High-affinity positive control clone for binding and neutralization assays. |
View F7 Products |
| Validator | F7 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View F7 Products |
| Related Target A | TF (Tissue Factor / CD142) The obligate cofactor for F7 activation; critical for initiating the extrinsic pathway. |
View TF Products |
| Related Target B | F10 (Factor X) The downstream substrate of the TF-F7a complex in the coagulation cascade. |
View F10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Post-Translational Gamma-Carboxylation | HEK293 expressed F7 ensures correct post-translational modification essential for calcium-dependent lipid binding. |
| Species Cross-Reactivity Screening | Human, Cynomolgus, and Mouse F7 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and active-site mutated negative controls included. |
| False Positives | Sequence-verified siRNA sets included for target knockdown and specificity validation. |
Live F7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for F7 therapeutics is intensifying, with major players shifting focus from traditional plasma-derived products to recombinant variants, long-acting glyco-engineered molecules, and tissue factor (TF)-targeting therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized coagulation control, tumor microenvironment modulation, and gene therapy vectors to provide sustained therapeutic levels without systemic bleeding risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (rFVIIa) | Novo Nordisk, LFB S.A. | Hemophilia A/B with inhibitors, FVII deficiency | Functional Activity Assay (Need native HEK293-expressed F7 for calcium-dependent activity) |
| Monoclonal Antibody / ADC | Genentech, Pfizer | Thrombosis, Solid Tumors (TF/FVIIa signaling) | Internalization & Blocking Assays (Need high-purity ECD-Fc and TF co-factors) |
| Gene Therapy / RNAi | Alnylam, Freeline Therapeutics | Congenital bleeding disorders, Thrombophilia | Expression Validation (Need Lentivirus for stable expression and siRNA for knockdown controls) |